Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Data ReadoutpositiveFasedienolPositive

AI Analysis

Summary

Vistagen announced topline results from a repeat dose study of fasedienol for acute treatment of social anxiety disorder, demonstrating favorable safety and tolerability comparable to single dose administration.

Clinical Trial Data

Phase

repeat dose study

Primary Endpoint

Met

Outcome Details

Repeat dose demonstrated favorable safety and tolerability similar to single dose

Importance:6/10

Sentiment:

0.60

clinical trialsafetytolerabilitysocial anxiety disordertopline results

Related Companies

$VTGN

Read the original article

Published by GlobeNewswire Clinical Studies on August 6, 2026 12:30 PM

Read Original